00:03 , May 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Cystine degradation boosts immunotherapies in melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Patient sample and mouse studies suggest promoting ferroptosis by degrading cystine could enhance the efficacy of anti-PD-1 immunotherapies in melanoma. In melanoma patients, high tumor levels of SLC7A11 and SLC3A2,...
21:32 , May 13, 2019 |  BC Extra  |  Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or...
23:04 , Apr 23, 2019 |  BC Innovations  |  Translation in Brief

J&J and Boston University identify classifications to catch lung cancer

J&J and Boston University identified a subtype of precancerous lesions with genomic alterations and immune cell deficiencies that could be used to diagnose and stratify patients at the earliest stages of lung cancer. The findings,...
22:58 , Apr 4, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

New Therapeutic Targets and Biomarkers: March 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March. Therapeutic targets are defined as any protein, gene or other molecule...
19:31 , Mar 31, 2019 |  BC Extra  |  Clinical News

Neon data highlights epitope spread as key metric for neoantigen vaccines

Interim results from Neon's Phase Ib trial of NEO-PV-01 plus Opdivo nivolumab suggest proof of epitope spread will be a telling readout for neoantigen cancer vaccines. The data also point to tumor microenvironment-based predictors of...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
12:20 , Mar 26, 2019 |  BC Innovations  |  Distillery Therapeutics

The short-chain fatty acid pentanoate for MS

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis Cell culture and mouse studies suggest the short-chain fatty acid pentanoate could help treat MS. In primary mouse T helper type 17 (Th17) cells pentanoate increased expression of...
01:31 , Mar 15, 2019 |  BC Innovations  |  Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
19:14 , Mar 14, 2019 |  BC Innovations  |  Emerging Company Profile

Silverback: Taking on tumoral myeloid cells

Silverback’s antibody-based conjugates stimulate innate and adaptive immunity by turning myeloid cells against tumors, while overcoming resistance to checkpoint inhibitors and other T cell-targeting immunotherapies. “When you are able to appropriately and potently activate myeloid...